Clinical Trials
10 trialsNCT00588991 2025-04-02
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed
NCT00462787 2013-11-14
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00005021 2013-07-11
Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma
Fox Chase Cancer Center
Phase 1 Completed
NCT00002625 2013-02-11
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002705 2013-02-01
Topotecan in Treating Children With Refractory Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002693 2011-08-03
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
Mayo Clinic
Phase 1 Completed
NCT00112619 2011-06-30
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
Pediatric Brain Tumor Consortium
Phase 1 Terminated
NCT00003331 2011-03-28
Combination Chemotherapy in Treating Patients With Advanced Cancer
NYU Langone Health
Phase 1 Completed
NCT00002588 2010-06-11
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00005593 2010-06-11
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
Case Comprehensive Cancer Center
Phase 1 Completed